EP3989955A1 - Procédé de soin de la peau ou du pelage d'animaux - Google Patents
Procédé de soin de la peau ou du pelage d'animauxInfo
- Publication number
- EP3989955A1 EP3989955A1 EP20734055.5A EP20734055A EP3989955A1 EP 3989955 A1 EP3989955 A1 EP 3989955A1 EP 20734055 A EP20734055 A EP 20734055A EP 3989955 A1 EP3989955 A1 EP 3989955A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- foam
- composition
- shampoo
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 241001465754 Metazoa Species 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 239000006260 foam Substances 0.000 claims abstract description 54
- 239000002453 shampoo Substances 0.000 claims abstract description 52
- 208000003251 Pruritus Diseases 0.000 claims abstract description 25
- 230000007803 itching Effects 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 7
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 230000036571 hydration Effects 0.000 claims description 3
- 238000006703 hydration reaction Methods 0.000 claims description 3
- 230000007794 irritation Effects 0.000 claims description 3
- 230000035807 sensation Effects 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 description 23
- 239000002253 acid Substances 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 15
- 150000003410 sphingosines Chemical class 0.000 description 10
- 201000008937 atopic dermatitis Diseases 0.000 description 9
- 206010012438 Dermatitis atopic Diseases 0.000 description 8
- 244000248557 Ophiopogon japonicus Species 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 239000007859 condensation product Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 206010003645 Atopy Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000003908 antipruritic agent Substances 0.000 description 4
- 229940033329 phytosphingosine Drugs 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical compound C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- -1 fatty alcohol monosulfosuccinates Chemical class 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 229960004955 oclacitinib Drugs 0.000 description 3
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229940046145 douxo calm Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QTDIEDOANJISNP-UHFFFAOYSA-N 2-dodecoxyethyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOCCOS(O)(=O)=O QTDIEDOANJISNP-UHFFFAOYSA-N 0.000 description 1
- KBHSAMYHDBBRKS-QTJGBDASSA-N 2-hydroxy-n-[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]benzamide Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)C1=CC=CC=C1O KBHSAMYHDBBRKS-QTJGBDASSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical class C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical class [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 150000001507 asparagine derivatives Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008408 compound extracted from plant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000003038 phytosphingosines Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Definitions
- the invention relates to a process for caring for the skin or the coat of pets, comprising the application of a composition of rinse-out shampoo type, followed by at least four consecutive applications of a composition in the form of non-rinsed foam.
- the invention also relates to a kit, in particular intended for implementing the method of caring for the skin and / or the coat of pets and in particular for helping to reduce their itching, comprising said compositions in compartments.
- atopic dermatitis is a chronic, itchy inflammatory dermatosis of multifactorial origin. This disorder results from complex interactions between genetic predisposing factors and environmental factors. The first signs of this disorder in dogs or cats usually appear between 6 months and 3 years old. Lesions mainly involve the face, extremities, major folds and abdomen. Atopic dermatitis or pruritus-like disorders associated with allergic dermatitis are most often treated with antipruritics, antihistamine agents, anti-inflammatory drugs or immunomodulators, such as ciclosporin, corticosteroids or oclacitinib. These treatments are usually accompanied by supportive or care treatments, such as shampoo treatments, to obtain better, faster results or to prevent or delay recurrence.
- the Applicant has developed a specific protocol for the application of compositions for the skin or the coat of pets that is simple to implement since it only comprises a single application of a rinse-off shampoo during said protocol, this single application of shampoo being followed by applications of compositions which do not require rinsing.
- This protocol provides very satisfactory results, especially in terms of reducing itching, while making the treatment easier to use and more attractive to owners, thus improving treatment compliance.
- the invention relates to a method of caring for the skin or the coat of an animal, preferably a pet, comprising the application to the skin or the coat of a shampoo to be rinsed out, followed by at least four consecutive applications to the skin or coat of a composition in the form of a leave-in foam.
- the process comprises the application of a rinse-out shampoo, followed by 5, 6, 7 or 8 consecutive applications of a composition in the form of a leave-in foam.
- the shampoo and the composition in the form of a leave-in foam are compositions comprising at least one compound intended to reduce the itching of animals and in particular of pets, such dogs or cats.
- the invention also relates to a kit, comprising in one or more compartment (s) at least one rinse-out shampoo and at least one composition in the form of a leave-in foam, and optionally an instruction leaflet detailing the method of use of said shampoo. and composition in the form of a leave-in foam, as defined in the present invention.
- FIG 1 shows the "control" protocol (A) and the protocol according to the invention (B) implemented in Example 1
- Figure 2 shows the results of studies (A) and (B) in the example (mean CADESI scores).
- the horizontal lines represented by dashes (-) correspond to the values delimiting the degree of severity (in remission / medium / moderate).
- the curve represented by broken lines (.7) is that of group (A).
- the horizontal line represented by dashes ( ⁇ -.) Corresponds to a threshold score of 40%.
- the curve represented by broken lines (.%) is that of group (A).
- the curve with a solid line (_) is that of group (B).
- the present invention therefore relates to a method for caring for the skin or coat of animals, in particular pets, comprising the application of a rinse-off shampoo to the skin or coat of an animal, followed by at least four consecutive applications to the skin or coat of said animal of a composition in the form of a leave-in foam.
- the method applied to the skin or coat of animals according to the invention can be carried out before, during or after treatment of animals exhibiting skin or coat disorders, and in particular disorders of the atopic dermatitis or pruritus or hyperseborrhea.
- the method of the invention can therefore be a treatment accompanying or supporting a therapeutic treatment, in particular treatments with antipruritic agents, antihistamine agents, anti-inflammatory agents or immunomodulatory agents, such as corticosteroids, cyclosporine or oclacitinib.
- the animals to be treated according to the method of the present invention may have previously been diagnosed atopic. They may possibly be in remission of clinical signs of atopic dermatitis. They may be being treated for their atopic condition, in particular being treated with antipruritic agents, antihistamine agents, anti-inflammatory agents or immunomodulatory agents.
- the method according to the invention can be implemented on animals exhibiting itching or having exhibited itching, optionally independently of a therapeutic treatment, in particular by the systemic route or in particular by injection or by the oral route, in particular with agents. antipruritics, antihistamines, anti-inflammatories or immunomodulators. Itching animals may be very mild or episodic, mild or somewhat more frequent, moderate or present with regular episodes, severe or present with prolonged episodes, or extremely severe or present almost continuously.
- the method of the invention makes it possible to reduce the itching of animals (or also called non-human mammals), in particular of pets, such as dogs or cats.
- the method according to the invention is characterized in that each application (subsequent to the first application) is carried out at least 24 hours or preferably at least 48 hours apart from the previous application.
- the method is implemented such that each of the foam applications consecutive and subsequent to the first application of the rinse-out shampoo is carried out between 24 h and 72 h after the previous application.
- each of the foam applications consecutive to and subsequent to the first application of the rinse-out shampoo is carried out between 36 hours and 72 hours, and in particular between 48 hours and 72 hours after the previous application.
- the time intervals between each application of non-rinsed foams can therefore vary between 24 hours and 72 hours, in particular between 36 hours and 72 hours, and more particularly between 48 hours (2 days) and 72 hours (3 days). In particular, it may be the protocol as described in Figure 1.
- the method according to the invention comprises the following steps: application of the shampoo (J1), application of the composition in the form of a leave-in foam (J3) carried out 48 hours from the shampoo (J1), followed by '' an application of the composition in the form of a leave-in foam (D6) carried out 72 hours after D3, followed by an application of the composition in the form of a leave-in foam (D8) carried out 48 hours after D6, followed by an application of the composition in the form of a leave-in foam (D10) produced 48 hours after D8, followed by an application of the composition in the form of a leave-in foam (D13) carried out 72 hours after D10, followed by an application of the composition in the form of of leave-in foam (D15) carried out 48 hours after D13, followed by an application of the composition in the form of a leave-in foam (D17) carried out 48 hours after D15, followed by an application of the composition in the form of a leave-in foam (D20) carried out 72 hours after D 17.
- the method comprises the application of a rinse-out shampoo, followed by 4, 5, 6, 7 or preferably 8 consecutive applications of a composition in the form of a leave-in foam.
- the 4, 5, 6, 7 or preferably 8 consecutive applications of leave-in foam according to the invention are not interrupted by an application of shampoo.
- the process according to the invention can be spread over a period of approximately 18 to 21 days. It can be repeated one, two or three times, or even more, if necessary.
- the method further comprises, after said at least 4, 5, 6, 7 or 8 consecutive applications of composition in the form of a leave-in foam, as defined above, at least one step consisting of an application of a rinse-off shampoo, said application of shampoo possibly being followed by consecutive applications of composition in the form of a leave-in foam, in particular said application of shampoo being able to be followed by at least 4 consecutive applications of composition in the form of non-rinsed foam, as described in the present invention.
- this additional step can be repeated several times, in particular one, two or three times.
- shampoo includes any composition intended to clean the hair or skin of non-human mammals and requires rinsing with water after application to the animal.
- shampoos have certain essential characteristics.
- the shampoos used in the present invention must of course be well tolerated compositions intended for topical application in non-human mammals.
- a shampoo has wetting, foaming and detergent properties to ensure satisfactory cleansing of the coat or skin.
- a shampoo composition of the invention contains surfactants, preferably at least one anionic, cationic, amphoteric or polar nonionic surfactant, or else a mixture of these.
- anionic surfactants there may be mentioned in particular: alkylsulphates (such as magnesium or sodium laurylsulphates), alkylethersulphates (such as laurylethersulphate), alkyl polyethersulphates, alkylsulphonates (alkyl groups having 8 to 18 carbon atoms). carbon), fatty acid soaps, fatty alcohol monosulfosuccinates, condensation products of fatty acids with isethionic acid, condensation products of fatty acids with methyltaurine, condensation products of fatty acids with sarcosine and condensation products of fatty acids with a protein hydrolyzate.
- alkylsulphates such as magnesium or sodium laurylsulphates
- alkylethersulphates such as laurylethersulphate
- alkyl polyethersulphates such as laurylethersulphate
- alkylsulphonates alkyl groups having 8 to 18 carbon atoms). carbon
- fatty acid soaps such as magnesium or sodium laurylsulphates
- cationic surfactants there may be mentioned in particular: long-chain quaternary ammonium compounds, esters of fatty acids and of amino alcohols and polyetheramines.
- esters of polyols and sugars condensation products of ethylene oxide with acids fatty, with fatty alcohols, with long chain alkylphenols, with long chain mercaptans and with long chain amides, and polyethers of polyhydric fatty alcohols.
- amphoteric surfactants there may be mentioned in particular: amino acid derivatives, such as asparagine derivatives, condensation products of monochloroacetic acid with imidazolines and alkylaminopropionates, more specifically derivatives of betaine or of imidazoline.
- amino acid derivatives such as asparagine derivatives, condensation products of monochloroacetic acid with imidazolines and alkylaminopropionates, more specifically derivatives of betaine or of imidazoline.
- the concentration of surfactants is preferably between 5 and 50% by weight relative to the total weight of the composition.
- the shampoos according to the invention can also contain other ingredients conventionally used in such compositions, such as agents which increase the viscosity, in particular acrylate / methacrylate copolymers, oils, waxes, plant extracts, emollients, agents. carbomers, gums, in particular xanthan gum, polyethylene glycols, cyclomethicones, conditioners, preservatives, such as methyl para-hydroxybenzoate or propyl parahydroxybenzoate, dyes, perfumes or mixtures thereof.
- Leave-in foams are therefore suitable for a leave-in application, ie the compositions are not removed by rinsing, and in particular by rinsing with water, after their application.
- Leave-in foams generally comprise a low concentration of surfactants, generally from 1 to 10%, and preferably from 2 to 4%, by weight relative to the total weight of the composition.
- the leave-in foams used in the present invention should of course be well-tolerated compositions intended for topical application in the non-human mammal.
- the leave-in foams that can be used in the present invention can be of different types. These may include:
- Aerosols in which the foam is generated by a propellant gas, so-called aerosol or spray foams,
- Foaming formulas not very rich in foaming surfactants but packaged in a packaging fitted with a mechanical foam generating system (pump with pulvorex type grid).
- non-human mammals or “animals” include all mammals except humans.
- non-human mammals are companion animals, including, without limitation, domestic animals such as especially dogs, cats, rabbits, ferrets and hamsters.
- the non-human mammals are cats and preferably dogs.
- compositions, shampoo and / or leave-in foam compositions used according to the invention are intended for cleaning or washing the skin and / or the coat. They can be used to maintain the health of the skin or coat of animals, in particular by maintaining the skin balance, by maintaining or improving the hydration of the skin, by soothing the skin, or by reducing or soothing the sensations of itching or irritation.
- the method for caring for the skin or coat of animals according to the invention is a method for cleaning or washing the skin and / or the coat, for maintaining the health of the skin or the coat of animals, to maintain the skin balance, to maintain or improve the hydration of the skin, to soothe the skin, or to reduce or soothe the sensations of itching or irritation.
- the compositions, shampoo and / or leave-in foam compositions used according to the invention further comprise at least one compound intended to treat or care for the skin or the coat of animals. It may in particular be at least one compound with moisturizing or restructuring properties, a compound intended to improve the barrier effect of the skin or restore its barrier effect, or intended to eliminate or reduce dandruff or excess sebum. , or even intended to reduce itching or help reduce dermatitis in animals, in particular pets.
- the leave-in compositions, shampoo and / or foam compositions used according to the invention can comprise, as active compounds, antimicrobials (compounds limiting the proliferation of bacteria, yeasts or fungi) or disinfectants, such as chlorhexidine.
- the compounds intended for treating or helping to care for the skin or the coat of animals can also be, for example, compounds of sphingoid base type or else compounds extracted from plants.
- the active compounds present in the compositions of the process according to the invention, shampoo and leave-in foam compositions are identical or different, preferably they are identical.
- the concentration of active compound intended to treat or help care for the skin or the coat is preferably between 0.001 and 30% by weight relative to the total weight. of the composition. More preferred concentrations may vary from 0.005 to 20% by weight%, 0.01 to 10% by weight%, 0.02-5% by weight% or 0.05 to 3% by weight%.
- Compounds obtained from a plant capable of acting on various factors of animal atopic dermatitis are particularly suitable for helping to reduce itching in animals. It is in particular a compound obtained from Ophiopogon japonicus, as described in particular in patent application WO2017121965. This compound is particularly suitable for use, in topical application to the skin or coat of animals, in an accompanying treatment for the care of atopic animals. It can be used on atopic skin in particular to help decrease or delay the rate of relapse, decrease the severity score of atopic dermatitis in animals (CADESI score), reduce the intensity and / or frequency of itching or pruritus, and more generally to improve the quality of life of the animal and / or its owner.
- CADESI score severity score of atopic dermatitis in animals
- active compound obtained from Ophiopogon japonicus within the meaning of the invention is meant any molecule or mixture of molecules obtained from Ophiopogon japonicus. They may be molecules native to the plant or molecules obtained by any type of transformation of the native molecules of the plant, for example by hydrolysis.
- the active compound according to the invention is preferably a hydrolyzate.
- hydrolyzate means any extract derived from Ophiopogon japonicus, obtained with a process comprising at least one enzymatic or chemical hydrolysis step of Ophiopogon japonicus, preferably at least one enzymatic hydrolysis step.
- Ophiopogon japonicus is meant all or part of the plant. It can be the whole plant or part of the plant. Preferably, they are tubers of Ophiopogon japonicus.
- Ophiopogon japonicus is a perennial, low and abundant herbaceous species with a rhizome of the Liliaceae family.
- the sphingoid base is preferably selected from the group consisting of sphingosine, sphinganine and phytosphingosine. Phytosphingosine is more particularly preferred. Suitable examples of sphingoid base derivatives include N-lactyloyl-phytosphingosine, N-salicyloyl-phytosphingosine or N-retinoylphytosphingosine, i.e. compounds which are N-substituted.
- sphingoid base derivatives include salts of sphingoid bases.
- the anion of the salt can be derived from any suitable acid, i.e., those acids which, when mixed with the sphingoid base in a suitable solid, produce a salt with improved water solubility. Acids which are themselves effective when applied to the coat or skin are preferred.
- Preferred salts of the sphingoid base for use in the composition of the present invention are the salts obtainable with acids which, when mixed with the above-mentioned sphingoid base in a suitable solvent, produce a salt having increased water solubility over the water solubility of the sphingoid base as such.
- Phytosphingosine salts are preferred for better solubility and better bioavailability.
- the acid is a hydrophilic acid capable of delivering the sphingoid base salt to the aqueous phase of the veterinary composition.
- Suitable hydrophilic acids include a-hydroxy alkanoic acid, an (hydroxy-3-alkanoic acid, an ⁇ , p-dihydroxy alkanoic acid, an alkanedioic acid or a mineral acid.
- Examples of preferred hydrophilic organic acids are. lactic acid, glycolic acid, malic acid, pyruvic acid, succinic acid, fumaric acid, ascorbic acid, gluconic acid and / or pyroglutamic acid, examples of acids preferred minerals are hydrochloric acid, nitric acid and / or phosphoric acid.
- the acid is a lipophilic organic acid to enable the effectiveness of the lipophilic acid and the sphingoid base in the sphingoid base salt to be increased.
- the method according to the invention may comprise one or more steps additional to those mentioned above, for example previous or subsequent steps. It is also possible to envisage repeating the successive steps of the process according to the invention. Thus, the protocol detailed in Figure 1 (B) can be repeated as many times as necessary, without requiring any downtime if deemed appropriate.
- An additional object according to the invention is a kit comprising in one or more compartment (s) at least one rinse-out shampoo and at least one composition in the form of a leave-in foam, and optionally an instruction manual detailing the method of use. of said shampoo and composition, as defined in the present invention.
- the composition in the form of a rinse-off foam can be presented in a single compartment or in several compartments. In the latter case, each compartment preferably comprises a composition in the form of a leave-in foam corresponding to each of the at least four consecutive applications.
- the kit has at least four compartments each comprising a composition in the form of a leave-in foam and another compartment comprising the shampoo to be rinsed out.
- Example 1 Treatment of dogs according to the present invention compared to a conventional protocol
- the aim of this study was to evaluate the effectiveness of a combination of shampoo and foam comprising phytosphingosine, from the range of products (Douxo Calm®, sold by the company Ceva Santé Animale) during a relapse crisis of atopic dermatitis in dogs.
- Douxo Calm® sold by the company Ceva Santé Animale
- the treatment consisted for the study (A) (control) of applications of a shampoo on D1, D8 and D15, and twice weekly applications of a leave-in foam between the applications of shampoo D1, D8 and J15 ( Figure 1 (A).
- Figure 2A shows the average changes in the CADESI score for each of the studies (A) and (B).
- a decrease in the CADESI score was observed during treatment ( Figure 2A).
- the mean percentage decrease was close to the expected threshold of -40% for group (A) and below the threshold of -40% for group (B), which means that in general after 21 days of treatment, CADESI is reduced on average by less than 40% ( Figure 2B).
- the mean percentages of CADESI change are -39.8 ⁇ 23.1% for group (A) and -75.6 ⁇ 19.0% for group (B).
- the primary endpoint was based on the percentage decrease in CADESI between D0 and D21. Thus, a higher percentage obtained can be used as the main criterion distinguishing the groups tested. Different percentages were tested (see Table 1). Table 1 provides information on the number of dogs that achieved the specific percentage decrease in CADESI. The 50% threshold corresponds to the level of difference observed between the two protocols, in fact only one dog reached this threshold for group (A), while 6 out of 7 dogs reached it in group (B).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19305857 | 2019-06-26 | ||
PCT/EP2020/067990 WO2020260559A1 (fr) | 2019-06-26 | 2020-06-26 | Procédé de soin de la peau ou du pelage d'animaux |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3989955A1 true EP3989955A1 (fr) | 2022-05-04 |
Family
ID=67303416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20734055.5A Pending EP3989955A1 (fr) | 2019-06-26 | 2020-06-26 | Procédé de soin de la peau ou du pelage d'animaux |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220249403A1 (fr) |
EP (1) | EP3989955A1 (fr) |
JP (1) | JP2022538051A (fr) |
CN (1) | CN114072126A (fr) |
AU (1) | AU2020303297A1 (fr) |
BR (1) | BR112021026318A2 (fr) |
CA (1) | CA3144540A1 (fr) |
WO (1) | WO2020260559A1 (fr) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101511333B (zh) * | 2006-10-13 | 2011-11-30 | 赢创戈尔德施米特有限公司 | 皮肤处理组合物 |
FI128215B (en) * | 2013-05-28 | 2019-12-31 | Argenlab Global Ltd | Low alcohol disinfection foam |
WO2016172412A1 (fr) * | 2015-04-23 | 2016-10-27 | The Procter & Gamble Company | Procédé d'administration/d'application ciblée sur les cheveux |
FR3046541B1 (fr) * | 2016-01-12 | 2018-02-09 | Societe Industrielle Limousine D'application Biologique | Principe actif obtenu a partir d'ophiopogon japonicus pour le traitement de la dermatite atopique |
CN110036063A (zh) * | 2016-11-14 | 2019-07-19 | 科思创聚合物(中国)有限公司 | 用于化妆施用的聚氨酯泡沫 |
EP3962431A4 (fr) * | 2019-05-01 | 2023-08-30 | Church & Dwight Co., Inc. | Composition de shampoing sans rinçage |
-
2020
- 2020-06-26 EP EP20734055.5A patent/EP3989955A1/fr active Pending
- 2020-06-26 AU AU2020303297A patent/AU2020303297A1/en active Pending
- 2020-06-26 BR BR112021026318A patent/BR112021026318A2/pt unknown
- 2020-06-26 CN CN202080047860.4A patent/CN114072126A/zh active Pending
- 2020-06-26 JP JP2021575966A patent/JP2022538051A/ja active Pending
- 2020-06-26 US US17/621,959 patent/US20220249403A1/en active Pending
- 2020-06-26 WO PCT/EP2020/067990 patent/WO2020260559A1/fr unknown
- 2020-06-26 CA CA3144540A patent/CA3144540A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020303297A1 (en) | 2022-02-24 |
WO2020260559A1 (fr) | 2020-12-30 |
CN114072126A (zh) | 2022-02-18 |
CA3144540A1 (fr) | 2020-12-30 |
JP2022538051A (ja) | 2022-08-31 |
US20220249403A1 (en) | 2022-08-11 |
BR112021026318A2 (pt) | 2022-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0975316B1 (fr) | Composition cosmetique a base de polyurethannes associatifs et de polymeres non ioniques a chaines grasses | |
EP0414608B1 (fr) | Nouvelles compositions cosmétiques contenant du chitosane et de la glucosamine | |
LU88145A1 (fr) | Composition pour le nettoyage de la peau, du cuir chevelu et des cheveux | |
EP0603019A1 (fr) | Dispersion aqueuse cosmétique ou dermatologique à base d'esters d'acide gras de sucre et de copolymères réticulés d'acrylamide | |
FR2840903A1 (fr) | Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux | |
EP1325731B1 (fr) | Agent microbicide et composition de traitement cosmétique le contenant | |
EP2074983B1 (fr) | Procédé de préparation de nanoémulsion cationique et composition cosmétique | |
EP1029534B1 (fr) | Compositions cosmétiques détergentes contenant un tensioactif hydroxyalkylether anionique et une gomme de guar cationique et leurs utilisations | |
EP1126817B1 (fr) | Compositions cosmetiques detergentes et utilisation | |
EP0906083B1 (fr) | Compositions cosmetiques detergentes a usage capillaire et utilisation | |
WO2020260559A1 (fr) | Procédé de soin de la peau ou du pelage d'animaux | |
EP2794012B1 (fr) | Utilisation de polysaccharides sulfatés comme agent antipelliculaire | |
EP1066822B1 (fr) | Composition de traitement antipelliculaire des cheveux et du cuir chevelu, à base d'actif antipelliculaire et d'hydroxyacide | |
EP0904045B1 (fr) | Compositions cosmetiques detergentes a usage capillaire et utilisation | |
EP0373988A1 (fr) | Composition cosmétique ou pharmaceutique pour le traitement des cheveux et du cuir chevelu | |
WO2000016739A1 (fr) | Utilisation d'au moins un derive de l'acide 10-hydroxy-2-decenoique dans une composition destinee a favoriser la desquamation de la peau | |
FR2820037A1 (fr) | Composition dermatologique a usage veterinaire comprenant une base sphingoide | |
WO2002085362A2 (fr) | Composition dermatologique comprenant l'acide nicotinique ou un amide, et une base sphingoïde. | |
FR2912052A1 (fr) | Composition a base de derives d'acides salicylique | |
EP0841893B1 (fr) | Association salicylate de zinc et extrait de serenoa repens pour le traitement de la seborrhee et compositions dermo-cosmetiques la comprenant | |
FR2820038A1 (fr) | Composition dermatologique a usage veterinaire comprenant une base sphingoide | |
FR3098394A1 (fr) | Composition comprenant au moins une oxazoline pour inhiber la croissance de levure du genre Malassezia impliquée notamment dans les croûtes de lait | |
FR2719215A1 (fr) | Procédé de traitement capillaire permettant d'éviter la fluidification du sébum, et composition capillaire correspondante. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220106 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230530 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240802 |